



## **Cesca Therapeutics Announces Exhibition at The Orthobiologic Institute's 9th Annual PRP & Regenerative Medicine Symposium**

June 6, 2018

### **Company's device subsidiary, ThermoGenesis, to exhibit its novel PXP™ cellular processing system at Booth 208**

RANCHO CORDOVA, Calif., June 06, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. ("Cesca" or the "Company") (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will be exhibiting its development-stage PXP™ System at The Orthobiologic Institute's (TOBI) 9<sup>th</sup> Annual PRP & Regenerative Medicine Symposium with Workshops & Cadaver Labs, which is being held June 7-9 in Las Vegas.

"In a mini review recently published in the peer-reviewed *Journal of Orthopedic Research and Therapy*, we report on the role of various bone marrow derived cells and cytokines used in the treatment of different orthopedic indications, such as knee osteoarthritis," said Dalip Sethi, Ph.D., Senior Director of Research and Development at Cesca. "Previous studies have identified a relationship between the presence of contaminating red blood cells (RBCs) and the decreased functionality of the stem and progenitor cells. The negative effect of contaminating RBCs is being discussed and debated in the field. To better understand the future potential of autologous stem cell-derived therapies, there is an urgent need for cell processing systems capable of extracting target cells with a higher degree of viability and purity. Cesca is pioneering this effort with its PXP System, for the processing of autologous bone marrow aspirates. As such, we are pleased to be able to exhibit this novel technology at this year's TOBI symposium."

Cesca's PXP System, once development is completed, will allow for the rapid processing of autologous bone marrow cells at the point-of-care. The System, which automates the volume reduction process, ensures consistently high recoveries of mononuclear cells (MNC), enriched in stem and progenitor cells. The System delivers a targeted volume and is capable of simultaneously processing multiple bone marrow units. The System does not require cell separation media or sedimentation agents.

The full text of the publication can be found at this link: [Bone Marrow Concentrate for Treatment of Knee Osteoarthritis: A Mini Review](#)

More information about the 2018 TOBI Symposium can be found [here](#).

#### **About TOBI 2018**

The Orthobiologic Institute's PRP & Regenerative Medicine Symposium is an annual gathering of approximately 500 clinicians, researchers, and industry professionals seeking to learn cutting-edge research and best practices in orthobiologic regenerative medicine.

#### **About Cesca Therapeutics Inc.**

Cesca Therapeutics Inc. (the "Company") develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis Corp., provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress™ platform to streamline the manufacturing process for the emerging CAR-T immunotherapy market.

#### **Company Contact:**

Cesca Therapeutics Inc.

Wendy Samford

916-858-5191

[ir@cescatherapeutics.com](mailto:ir@cescatherapeutics.com)

**Investor Contact:**

Rx Communications

Paula Schwartz

917-322-2216

[pschwartz@rxir.com](mailto:pschwartz@rxir.com)

Source: Cesca Therapeutics Inc.